Abiraterone-sensitive prostate cancer cells revealed much higher MYB levels than abiraterone-resistant cells, and the reduction of MYB signaling seemed responsible for the development of abiraterone resistance[111]. This evidence concerns the gene MYB and prostate carcinoma.